

Bivalent mRNA COVID-19 Vaccines: Recap

- **Bivalent** mRNA COVID-19 vaccines authorized and recommended to be used for **all doses** administered to individuals 6 months of age and older.
- **Monovalent** mRNA COVID-19 vaccines no longer authorized and recommended for use (deauthorization of monovalent product **not** related to safety concerns)
- Additional bivalent mRNA dose available for people 65+ and with certain kinds of immunocompromise authorized

People ages 65 years and older have the option to receive 1 additional bivalent mRNA vaccine dose at least 4 months after the first dose of a bivalent mRNA vaccine. If Moderna is used, administer 0.5 mL/50 ug (dark blue cap and label with a gray border); if Pfizer-BioNTech is used, administer 0.3 mL/30 ug (gray cap and label with a gray border).

Non-mRNA Vaccines

- Novavax
 - People ages 12 years and older who previously received 1 or 2 monovalent Novavax primary series dose(s) are recommended to receive 1 bivalent mRNA vaccine dose.
 - The monovalent Novavax COVID-19 Vaccine remains authorized for use as a 2-dose primary series and as a booster dose in certain limited situations.
- Janssen (Johnson & Johnson) COVID-19 Vaccine
 - Janssen COVID-19 Vaccine has been removed as the vaccine is no longer available in the United States.
 - People ages 18 years and older who received 1 or 2 Janssen COVID-19 Vaccine dose are recommended to receive 1 bivalent mRNA dose (Moderna or Pfizer-BioNTech) at least 2 months after completion of the previous dose.



When Are You Up to Date?

Everyone aged 6 years and older

You are up to date when you get **1 updated Pfizer-BioNTech or Moderna COVID-19 vaccine**.

Children aged 6 months—5 years who got the Pfizer-BioNTech COVID-19 vaccine

You are up to date if you are:

- Aged 6 Months—4 years and you get 3 COVID-19 vaccine doses, including at least 1 updated COVID-19 dose.
- Aged 5 years and you get at least 1 updated COVID-19 vaccine dose.

Children aged 6 months—5 years who got the Moderna COVID-19 vaccine

You are up to date when you get 2 Moderna COVID-19 vaccine doses, including at least 1 updated COVID-19 vaccine dose.

People who are unable or choose not to get a recommended mRNA vaccine

You are up to date when you get the Novavax COVID-19 vaccine doses approved for your age group.

People who got the Johnson & Johnson/Janssen COVID-19 vaccine

You are up to date when you get 1 updated COVID-19 vaccine.



CDC: Updated Guidance Tables

COVID-19 Vaccination Guidance for People who are **not** Moderately or Severely Immunocompromised

CDC Table 1 for mRNA COVID-19 vaccines

- **Ages 6 Months – 4 Years**
- **Age 5 Years**
- **Ages 6 Years – 11 Years**
- **Ages 12 Years and Older**

COVID-19 vaccination history	Bivalent vaccine	Number of bivalent doses indicated	Dosage (mL/ug)	Vaccine vial cap and label colors	Interval between doses*
Unvaccinated	Moderna	2	0.25 mL/25 ug	Dark blue cap; gray label border	Dose 1 and Dose 2: 4-8 weeks
	— <i>or</i> — Pfizer BioNTech [†]	3	0.2 mL/3 ug	Maroon	Dose 1 and Dose 2: 3-8 weeks Dose 2 and dose 3: At least 8 weeks
1 dose monovalent Moderna	Moderna	1	0.25 mL/25 ug	Dark blue cap; gray label border	4-8 weeks after monovalent dose
2 doses monovalent Moderna	Moderna	1	0.2 mL/10 ug	Dark pink cap; yellow label border	At least 8 weeks after last monovalent dose
2 doses monovalent Moderna and 1 dose bivalent Moderna	NA; previously received 1 bivalent vaccine dose	NA	NA	NA	NA
1 dose monovalent Pfizer-BioNTech	Pfizer BioNTech [†]	2	0.2 mL/3 ug	Maroon	Dose 1: 3-8 weeks after monovalent dose Dose 1 and Dose 2: At least 8 weeks
2 doses monovalent Pfizer-BioNTech	Pfizer BioNTech	1	0.2 mL/3 ug	Maroon	At least 8 weeks after last monovalent dose
3 doses monovalent Pfizer-BioNTech	Pfizer BioNTech	1	0.2 mL/3 ug	Maroon	At least 8 weeks after last monovalent dose
2 doses monovalent Pfizer-BioNTech and 1 dose bivalent Pfizer-BioNTech	NA; previously received 1 bivalent vaccine dose	NA	NA	NA	NA

Above Example: Table 1 for Ages 6 months – 4 Years





CDC: Updated Guidance Tables

COVID-19 Vaccination Guidance for People who are Moderately or Severely Immunocompromised

CDC Table 2 for mRNA COVID-19 vaccines

- **Ages 6 Months – 4 Years**
- **Age 5 Years**
- **Ages 6 Years – 11 Years**
- **Ages 12 Years and Older**



COVID-19 vaccination history	Bivalent vaccine	Number of bivalent doses indicated*	Dosage (mL/ug)	Vaccine vial cap and label colors	Interval between doses
Unvaccinated	Moderna — <i>or</i> — Pfizer BioNTech†	3	0.25 mL/25 ug	Blue cap; gray label border	Dose 1 and Dose 2: 4 weeks Dose 2 and Dose 3: At least 4 weeks
		3	0.2 mL/3 ug	Maroon	Dose 1 and Dose 2: 3 weeks Dose 2 and dose 3: At least 8 weeks
1 dose monovalent Moderna	Moderna	2	0.25 mL/25 ug	Blue cap; gray label border	Dose 1: 4 weeks after monovalent dose Dose 1 and Dose 2: At least 4 weeks
2 doses monovalent Moderna	Moderna	1	0.25 mL/25 ug	Blue cap; gray label border	At least 4 weeks after last monovalent dose
3 doses monovalent Moderna	Moderna	1	0.2 mL/10 ug	Dark pink cap; yellow label border	At least 8 weeks after last monovalent dose
3 doses monovalent Moderna and 1 dose bivalent Moderna	—	See footnote	—	—	—
1 dose monovalent Pfizer-BioNTech	Pfizer- BioNTech†	2	0.2 mL/3 ug	Maroon	Dose 1: 3 weeks after monovalent dose Dose 1 and Dose 2: At least 8 weeks
2 doses monovalent Pfizer-BioNTech	Pfizer- BioNTech	1	0.2 mL/3 ug	Maroon	At least 8 weeks after last monovalent dose
3 doses monovalent Pfizer-BioNTech	Pfizer- BioNTech	1	0.2 mL/3 ug	Maroon	At least 8 weeks after last monovalent dose
2 doses monovalent Pfizer-BioNTech and 1 dose bivalent Pfizer-BioNTech	—	See footnote	—	—	—
3 doses of monovalent Pfizer-BioNTech and 1 bivalent Pfizer-BioNTech dose	—	See footnote	—	—	—

Above Example: Table 2 for Ages 6 months – 4 Years



COVID-19 Vaccine Timing Guide Updated!

COVID-19 Vaccine Timing—Routine Schedule

Vaccinate ALL 58

Age*	Vaccine	If unvaccinated:	If had monovalent doses give bivalent (B) doses:
6 months–4 years	Pfizer–Infant/Toddler Bivalent	1st Dose → 3-8 weeks → 2nd Dose → ≥8 weeks → 3rd Dose	If 1 prior dose, then: 3-8 weeks B ≥8 weeks B If 2-3 prior doses, then: ≥8 weeks B
6 months–5 years	Moderna–Bivalent	1st Dose → 4-8 weeks → 2nd Dose Use blue cap vial, 0.25mL	If 1 prior dose, then†: 4-8 weeks B Blue cap, 0.25mL If 2 prior doses then‡: ≥2 months B Pink cap, 0.2mL
6+ years [§]	Moderna–Bivalent	1 Dose → ≥4 months → Ages 65+ optional 2nd bivalent dose (Moderna/Pfizer) Use blue cap vial, 6-11 years: 0.25mL, 12+ years: 0.5mL	
5–11 years [¶]	Pfizer–Pediatric Bivalent	1 Dose	If 1 or more prior doses (of any of the 4 brands), then†: ≥2 months Bivalent (Moderna/Pfizer)
12+ years	Pfizer/Adol/Adult Bivalent	1 Dose → ≥4 months → Ages 65+ optional 2nd bivalent dose (Moderna/Pfizer)	(Ages 65+ may receive 1 additional bivalent dose ≥4 months after 1st)
12+ years	Novavax ^{††} Monovalent	1st Dose → 3-8 weeks → 2nd Dose →	
18+ years	Janssen (J&J) Monovalent Expired	Dose given before expiration →	

* See CDC recommendations for children transitioning from a younger to older age group
 ** An 8-week interval may be preferable for some people, especially for males 12-39 years.
 † Please note the Moderna bivalent dosages differ for ages 6-11 (0.25 mL, 25 mcg) and 12+ (0.5 mL, 50 mcg).
 ‡ Children 5 years of age who had 1 or more doses of Moderna monovalent vaccine may receive Moderna or Pfizer bivalent vaccine.
 † Children 5 years of age who had 1 or more doses of Pfizer monovalent vaccine are only eligible to receive Pfizer bivalent vaccine.
 ‡ People 18+ years who have not received any booster doses and are unable or unwilling to receive a bivalent booster, may receive the monovalent Novavax booster as a single booster dose at least 6 months after their primary series.
 View Interim Clinical Considerations for Use of COVID-19 Vaccines for details. Schedule is subject to change.

California COVID-19 Vaccination Program IMM-1396 (5/10/23) Page 1 of 3

COVID-19 Vaccine Timing if Moderately/Severely Immunocompromised

Vaccinate ALL 58

Children and Adolescents (Ages 6 months–17 years)

Age	Vaccine	If unvaccinated**:	If had prior monovalent doses give bivalent (B) doses**:
6 months–4 years	Pfizer Bivalent–Infant/Toddler	1st Dose → 3 weeks → 2nd Dose → ≥8 weeks → 3rd Dose → ≥2 months → Optional Dose*	1 Monovalent 3 w B ≥8 w B 2-3 Monovalent ≥8 w B Optional Dose* ≥2 m
5–11 years	Pfizer Bivalent–Pediatric	1st Dose → 3 weeks → 2nd Dose → ≥4 weeks → 3rd Dose → ≥2 months → Optional Dose*	1 Monovalent† 3 w B ≥4 w B 2 Monovalent† ≥4 w B Optional Dose* ≥2 m
12+ years	Pfizer Bivalent–Adol/Adult	Use orange cap for 5-11 years and gray cap for 12+ years	
6+ months	Moderna Bivalent	1st Dose → 4 weeks → 2nd Dose → ≥4 weeks → Use blue cap vial, 6 months-11 years	
12+ years	Novavax Monovalent	1st Dose → 3 weeks → 2nd Dose →	

* An optional dose may be given ≥2 months after the last dose. Further doses may be given at the healthcare provider's discretion. See Table 2 for vial and dosage.
 † Heterologous "mix-and-match" dosing is allowed for ages 6 years and older.
 ‡ Children 5 years of age who had 1 or more doses of Pfizer monovalent vaccine are only eligible to receive Pfizer bivalent vaccine.
 † Children 5 years of age who had 1 or more doses of Moderna monovalent vaccine may receive Moderna or Pfizer bivalent vaccine.
 View Interim Clinical Considerations for Use of COVID-19 Vaccines for details. Schedule is subject to change.

California COVID-19 Vaccination Program

COVID-19 Vaccine Timing if Moderately/Severely Immunocompromised

Vaccinate ALL 58

Adults (Ages 18 years and older)

Vaccine	If unvaccinated**:	If had prior monovalent doses give bivalent (B) doses**:
Moderna–Bivalent (blue cap/gray border)	1st Dose → 4 weeks → 2nd Dose → ≥4 weeks → 3rd Dose → ≥2 months → Optional Dose* Use blue cap vial, 0.5mL (50mcg), for 12+ years.	1 Monovalent 4 w B ≥4 w B 2 Monovalent ≥4 w B 3 Monovalent ≥8 w B Optional Dose* (Moderna/Pfizer) ≥2 m
Pfizer–Bivalent Adol/Adult (gray cap)	1st Dose → 3 weeks → 2nd Dose → ≥4 weeks → 3rd Dose → ≥2 months → Optional Dose*	1 Monovalent 3 w B ≥4 w B 2 Monovalent ≥4 w B 3 Monovalent ≥8 w B Optional Dose* (Moderna/Pfizer) ≥2 m
Novavax ^{††} Monovalent	1st Dose → 3 weeks → 2nd Dose →	If 1 or 2 prior doses, then: ≥8 weeks Bivalent (Moderna/Pfizer) ≥2 m Optional Dose* (Moderna/Pfizer)
Janssen (J&J) Monovalent Expired	Dose given before expiration →	If 1 or 2 prior doses, then: ≥4 weeks Bivalent (Moderna/Pfizer) ≥2 m Optional Dose* (Moderna/Pfizer)

* An optional dose may be given ≥2 months after the last dose. Further doses may be given at the healthcare provider's discretion. See Table 2 for vial and dosage.
 † Heterologous "mix-and-match" dosing is allowed for ages 6 years and older.
 ‡ People 18+ years who have not received any booster doses and are unable or unwilling to receive a bivalent booster, may receive the monovalent Novavax booster as a single booster dose at least 6 months after their primary series.
 View Interim Clinical Considerations for Use of COVID-19 Vaccines for details. Schedule is subject to change.

California COVID-19 Vaccination Program IMM-1396 (5/10/23) Page 3 of 3

UPDATED COVID-19 VACCINE FAQs FOR LONG-TERM CARE SETTINGS

Updated 5/22/23 to reflect CDC's updated COVID-19 vaccine recommendations.

ELIGIBILITY

1. Who is eligible to receive an updated COVID-19 vaccine?

- Updated COVID-19 vaccines are recommended for everyone 6 months and older. People 6 years and older should receive 1 updated vaccine. For young children, recommendations depend on their vaccination history.
- People 65 years and older may receive 1 additional updated dose 4 months or more after their 1st updated dose.
- People with moderate or severe immunocompromise may receive 1 or more additional updated doses 2 months or more after their 1st updated dose (talk to your healthcare provider for more information).

Timing and other details are available at bit.ly/timingguide.

2. Which updated vaccines are available?

- Moderna COVID-19 vaccine, bivalent (original and omicron BA.4/BA.5) for use in individuals 6 months and older.
- Pfizer-BioNTech COVID-19 vaccine, bivalent (original and omicron BA.4/BA.5) for use in individuals 6 months and older.

3. What if someone recently had a COVID-19 infection?

- Defer COVID-19 vaccination until recovery from the acute illness (if symptoms were present) and criteria to discontinue isolation have been met. People who recently had a SARS-CoV-2 infection **may** consider delaying COVID-19 vaccination by 3 months from symptom onset or positive test (if infection was asymptomatic). For more information, refer to [Interim Clinical Considerations for Use of COVID-19 Vaccines](#).

4. Can the original monovalent vaccines still be used?

- Monovalent mRNA COVID-19 vaccines are no longer authorized for use.
- The monovalent Novavax COVID-19 vaccine remains authorized for use as a 2-dose primary series for people 12 years and older, and as a booster dose in certain limited situations.

5. Can COVID-19 vaccines and other vaccines be administered at the same time?

- Yes, routine administration of all age-appropriate doses of vaccines simultaneously is recommended for people for whom no specific contraindications exist at the time of the healthcare visit.

BENEFITS AND RISKS

6. Who might benefit most from getting an updated vaccine now?

- [Older adults](#), especially those who are unvaccinated.
- People who are [immunocompromised](#).
- People with [medical conditions](#) that increase risk of getting very sick from COVID-19 (e.g., people with heart, lung, or kidney disease; diabetes; or dementia).
- People who live with someone who is immunocompromised, at higher risk for severe disease, or can't be vaccinated due to age or other reasons.
- People who are at higher risk of exposure to COVID-19 (e.g., live or work in a LTCF or in a community where the COVID-19 level is high).

7. What are the benefits of an updated vaccine?

- [Updated COVID-19 vaccines provide significant additional protection](#) against hospitalization and death. Updated COVID-19 vaccines target newer omicron variants of the COVID-19 virus.
- [COVID-19 is the third leading cause of death in the U.S. and vaccines can prevent many of these deaths](#).

8. What are the risks of an updated vaccine?

- The most common side effects of COVID-19 vaccines include redness and swelling at the injection site, fatigue, and fever.

ADDITIONAL INFORMATION

9. How should LTCFs promote updated COVID-19 vaccines?

- LTCFs **should offer** updated vaccines to eligible residents and staff.
- LTCFs should inform eligible residents and staff about current recommendations and how to access updated vaccine doses ([MyTurn](#) and [Vaccines.gov](#)).

RESOURCES

- [LTCF COVID-19 Vaccine Toolkit](#)
- [COVID-19 Vaccine Resources for Long-Term Care Facilities](#)
- [CDC Interim Clinical Considerations for Use of COVID-19 Vaccines](#)



May is Nurses Appreciation Month and Older Californians Month! Archived Webinars

Archived [COVID-19 Crucial Conversations](#) webinars:

- **Strategies for Nurses to Build Trust with Vaccine-Hesitant Patients**
 - [Slides](#) | [Recording](#)
- **Talking with Older Adults about COVID-19 Vaccines and Treatment**
 - [Slides](#) | [Recording](#)




Older Californians Month – May 2023

- Intended to recognize the invaluable contributions of millions of older adults to our past, present, and future.
- California is home to more than nine million residents aged 60 or older.
- By the end of the decade, 11 million Californians will be age 60 or older, and over one million will be 85 or older.
- Older Californians enrich our families, communities, and economy through diverse life experiences, cultures, and contributions.



Digital Vaccine Record (DVR)

Users can now retrieve both their COVID-19 Vaccine Records and California Immunization Records!



- Includes all routine immunizations
- Shows vaccines that may be overdue, upcoming & completed
- Available in multiple languages (Simplified & Traditional Chinese, Arabic, Spanish, Tagalog, Vietnamese, Korean)
- **May be used as documentation for school or child care immunization requirements**

<https://MyVaccineRecord.cdph.ca.gov>

Digital Vaccine Record

GET YOUR DIGITAL VACCINE RECORD



Private. Convenient. Secure.

What is a Digital Vaccine Record (DVR)?
Your Digital Vaccine Record (DVR) is an electronic vaccination record from the California Immunization Registry (CAIR) and is an official record of the state of California.

What information does the DVR include?
The DVR has your name, date of birth, vaccination dates, and the vaccines you received.

Where do I access my Digital Vaccine Record?
Visit myvaccinerecord.cdph.ca.gov to access your record. You will need to enter your first and last name, date of birth, and mobile number or email address. You will create a PIN which will be required to obtain your DVR when the link to your record is provided to you.

What digital records can I access from the DVR Portal?
There are two types of records you can access from the DVR Portal:

- **COVID-19 QR code** that (when scanned by a SMART Health Card reader) will display the same information as your paper CDC vaccine card: your name, date of birth, vaccination dates, and vaccines.
- **Record of all your vaccinations** that were reported by pharmacies and healthcare providers to CAIR. Note that your historical vaccinations may not have been reported to CAIR.




 For more DVR questions, visit myvaccinerecord.cdph.ca.gov/faq or call 1-833-422-4255 (open M-F 8AM-8PM, SA-SU 8AM-5PM).

California Department of Public Health, Immunization Branch IMM-1461 (3/9/23)

OBTENGA SU REGISTRO DIGITAL DE VACUNACIÓN



PRIVADO. CONVENIENTE. SEGURO.

Registro Digital de Vacunación (DVR)
Su Registro Digital de Vacunación (DVR, por sus siglas en inglés) es un registro electrónico de vacunación procedente del Registro de Vacunación de California (CAIR, por sus siglas en inglés) y es un registro oficial del estado de California.

¿Qué información incluye el DVR?
El DVR tiene su nombre, fecha de nacimiento, fechas de vacunación y las vacunas que recibió.

¿Dónde accedo mi Registro Digital de Vacunación?
Visite myvaccinerecord.cdph.ca.gov para acceder su registro. Necesita ingresar su primer nombre y apellido, fecha de nacimiento y número de celular o correo electrónico. Necesitará crear un PIN para poder obtener su DVR cuando se le proporcione el enlace a su registro.

¿Qué registros digitales puedo acceder desde el Portal DVR?
Hay dos tipos de registros a los que puede acceder desde el Portal DVR:


- **Código QR de COVID-19** que (cuando es escaneado por un lector de tarjetas SMART Health) mostrará la misma información que su tarjeta de papel de los CDC: su nombre, fecha de nacimiento, fechas de vacunación y las vacunas.
- **Registro de todas las vacunas** que informaron las farmacias y otros proveedores de salud a CAIR. Tome en cuenta que es posible que su historial de vacunación no se haya ingresado a CAIR.




 Para más preguntas sobre el DVR, visite myvaccinerecord.cdph.ca.gov/faq-es/ o llame al 1-833-422-4255 (L-V 8AM-8PM, S-D 8AM-5PM).

California Department of Public Health, Immunization Branch IMM-1461S (3/30/23)

Found on <https://eziz.org/covid/>



ENHANCED BY Google

Program Updates

Program Enrollment

My Turn

Vaccine Management

Vaccine Administration

Reporting Requirements

Archived Communications

Patient Resources

Provider Support

COVID-19 Provider Call Center

Email: Program Info
Phone: (833) 502-1245
Hours: Mon-Fri, 8AM-6PM

Contact us for questions about the program or help with accessing documents.

myCAvax and My Turn

Email: myCAvax Technical Support
MyTurn Onboarding, MyTurn Technical Support
Phone: (833) 502-1245
Mon-Fri, 8AM-6PM

My Turn Clinic Translation

Patient Resources

Jump to Topic:

- General Information
- Factsheets, Flyers, and FAQs
- Myths and Misinformation
- Special Populations
- In-language (Translated) Resources
- Campaigns and Toolkits
- Mental Wellness Resources

General Information

- COVID-19 Vaccine Info for the Public: CDC | California (Available in multiple languages) 1/23
- COVID-19 Vaccines and Allergic Reactions (CDC): Chinese, English, Korean, Spanish, Vietnamese, and others 7/22
- Digital COVID-19 Vaccine Record (CDPH): Arabic, Chinese, English, Korean, Spanish, Tagalog, Vietnamese 7/22
- Myocarditis and Pericarditis after Vaccination (CDC): Chinese, English, Korean, Spanish, Vietnamese, and others 9/22
- Vaccine Recipient Education: Talking to Recipients about COVID-19 Vaccines (CDC) 4/22

Factsheets, Flyers, and FAQs

- Your COVID-19 Vaccination (CDC): Chinese, English, Korean, Spanish, Vietnamese 7/22
- COVID-19 Vaccination FAQs (CDC): Chinese, English, Korean, Spanish, Vietnamese, and others 2/23
- Get Vaccine Answers website (Ad Council and COVID Collaborative): Chinese, English, Haitian, Korean, Spanish, Russian, Vietnamese
- How to Talk to Your Patients about COVID-19 Vaccine (CDC) 11/21
- Know the Benefits and Risks for COVID-19 Vaccine fact sheet for lower-literacy audience (CDPH) 6/21 - Spanish, Vietnamese
- **Get Your Digital Vaccine Record flyer | Spanish**

[Get Your Digital Vaccine Record](#) | [Arabic](#) | [Chinese \(Simplified\)](#) | [Chinese \(Traditional\)](#) | [Korean](#) | [Tagalog](#) | [Vietnamese](#)

Upcoming Meetings

FDA Vaccines and Related Biologic Products (VRBPAC) Meeting



Topic: Discuss and make recommendations on the selection of strain(s) to be included in the periodic updated COVID-19 vaccines for the 2023-2024 vaccination campaign

When: Thursday, June 15, 2023, 5:30AM-2PM

[Meeting Information](#) | [Meeting Webcast](#)

CDC Advisory Committee on Immunization Practices (ACIP) Meeting

Topics: Updates on multiple vaccines, including COVID-19 vaccines

When: Wednesday to Friday, June 21 to 23, 2023



[Draft Agenda](#) | [Meeting Webcast](#)